文献速递泌尿生殖与妇科肿瘤放疗

局限期前列腺癌常规与大分割IMRT长期患者报告结局的3期随机试验

Long-Term Patient-Reported Outcomes From a Phase 3 Randomized Prospective Trial of Conventional Versus Hypofractionated Radiation Therapy for Localized Prostate Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2016-12-28

该3期随机试验比较局限期前列腺癌患者接受常规IMRT(76 Gy/38次)与大分割IMRT(70.2 Gy/26次)的长期生活质量。结果显示两组EPIC、IPSS、EQ5D评分随时间无统计学显著差异,大分割组EPIC尿失禁评分有偏低趋势,多变量分析中分割方案与任何生活质量参数无关联。

要点

  • 两组EPIC、IPSS、EQ5D评分随时间无显著差异
  • 大分割组EPIC尿失禁评分相对基线偏低者更多
  • 多变量分析中分割方案与生活质量参数无关联

核心结论

  • 在局限期前列腺癌中,大分割IMRT与常规IMRT的长期生活质量变化总体稳定,两者无统计学显著差异,大分割IMRT可能是可接受的治疗方式。

研究设计与样本

  • 2002至2006年纳入303例低危至高危局限期前列腺癌患者的3期随机前瞻性试验,随机接受76 Gy/38次常规IMRT或70.2 Gy/26次大分割IMRT。
  • 生活质量分析分别有286例(EPIC)、299例(IPSS)、218例(EQ5D)具备基线数据并纳入分析,采用logistic混合效应回归模型评估治疗效应。

主要发现

  • 两组EPIC、IPSS、EQ5D评分随时间无统计学显著差异,但大分割组EPIC尿失禁评分有偏低趋势。
  • 长期随访中大分割组相对基线EPIC尿失禁评分偏低者多于常规IMRT组。
  • 多变量分析未发现放疗分割方案与任何生活质量参数相关。
  • 接受淋巴引流区放疗者EPIC激素评分较未接受者更差。
  • 除EPIC激素评分与EQ5D评分外,生活质量结局总体随时间稳定。

关键数值与推荐

  • 主要结局为最小临床重要差异,定义为各生活质量参数相对基线0.5个标准差的变化。
  • 常规IMRT方案为76 Gy分38次,大分割IMRT方案为70.2 Gy分26次。
  • 生活质量工具包括EPIC、IPSS与EQ5D问卷。

临床怎么用

  • 本结果支持大分割IMRT作为临床局限期前列腺癌可接受的治疗选择。
  • 随访中可关注大分割IMRT患者的尿失禁症状及淋巴引流区放疗者的激素相关生活质量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess the long-term quality of life (QoL) outcomes from a phase 3 trial comparing 2 modes of intensity modulated radiation therapy (IMRT): conventional IMRT (CIMRT) versus hypofractionated IMRT (HIMRT) in patients with localized prostate cancer. METHODS AND MATERIALS: Between 2002 and 2006, 303 men with low-risk to high-risk prostate cancer were randomized to 76 Gy in 38 fractions (CIMRT) versus 70.2 Gy in 26 fractions (HIMRT). QoL was compared by use of the Expanded Prostate Cancer Index Composite (EPIC), the International Prostate Symptom Score (IPSS), and EuroQoL (EQ5D) questionnaires. The primary outcome of the QoL analysis was a minimum clinically important difference defined as a 0.5 standard deviation change from baseline for each respective QoL parameter. Treatment effects were evaluated with the use of logistic mixed effects regression models. RESULTS: A total of 286, 299, and 218 patients had baseline EPIC, IPSS, or EQ5D data available and were included in the analysis. Overall, there was no statistically significant difference between the 2 treatment arms in terms of EPIC, IPSS, or EQ5D scores over time, although there was a trend toward lower EPIC urinary incontinence scores in the HIMRT arm. More patients in the HIMRT arm had a lower EPIC urinary incontinence score relative to baseline versus patients in the CIMRT arm with long-term follow-up. On multivariable analysis, there was no association between radiation fractionation scheme and any QoL parameter. When other clinical factors were examined, lymph node radiation was associated with worse EPIC hormonal scores versus patients receiving no lymph node radiation. In general, QoL outcomes were generally stable over time, with the exception of EPIC hormonal and EQ5D scores. CONCLUSIONS: In this randomized prospective study, there were stable QoL changes in patients receiving HIMRT or CIMRT. Our results add to the growing body of literature suggesting that HIMRT may be an acceptable treatment modality in clinically localized prostate cancer.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Shaikh T, Li T, Handorf EA, et al. Long-Term Patient-Reported Outcomes From a Phase 3 Randomized Prospective Trial of Conventional Versus Hypofractionated Radiation Therapy for Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. 2016. PMID: 28244407. doi:10.1016/j.ijrobp.2016.12.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。